Special Focus Editor's Corner

Cancer vaccines: Are we there yet?

Volume 8, Issue 8   August 2012
Pages 1161 - 1165
http://dx.doi.org/10.4161/hv.21660
Authors: Michael G. Hanna, Jr.

View affiliations

Abstract:
For nearly two decades there has been an abundance of research and clinical development programs underway to develop active specific immunotherapies, to educate the patient’s immune response, specifically the T-cell immunity and memory, to recognize and destroy tumor cells by cell-mediated cellular toxicity. While many of these technology platforms achieved promising results in preclinical and clinical phase I and II clinical trials, essentially all but one have failed to achieve FDA market approval as a therapeutic drug product.

Received: July 9, 2012; Accepted: July 29, 2012; Published Online: August 1, 2012

Preview:



Advertisements